Updated Overall Survival Results From MONALEESA-3 Show Improved Overall Survival in Patients With HR-Positive/HER2-Negative Breast Cancer - The ASCO Post
ESMO-BC 2022: Updated overall survival (OS) results from the first-line (1L) population in the Phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2? advanced breast cancer (ABC) treated with ribociclib (RIB) +
Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients | Novartis
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
MONALEESA-3: Ribociclib Plus Fulvestrant Improves Overall Survival Over Fulvestrant Alone in the First-Line Setting - The ASCO Post
Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer - LifeProNow LifeProNow
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - Annals of Oncology
Efficacy of KISQALI® (ribociclib) + AI in Postmenopausal | HCP
ASCO 2021: [VIRTUAL] Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer | British Journal of Cancer
Efficacy of KISQALI® (ribociclib) + Fulvestrant in Postmenopausal | HCP
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Ribociclib for the first-line treatment of advanced hormone receptor-positive breast cancer: a review of subgroup analyses from the MONALEESA-2 trial | Breast Cancer Research | Full Text
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study - ScienceDirect
Kisqali extends survival by 1 year in advanced breast cancer < Pharma < Article - KBR
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Ribociclib (Kisqali)/Fulvestrant Extends Life in HR+/HER2- Advanced Breast Cancer
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treat